Cantargia AB…reported that the ﬁrst patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current or previous smokers with multifocal high-risk lung nodules, and therefore at risk of developing lung cancer

nadunolimab (CAN04) - Cantargia

Jun 10, 2026